Company Overview
Snapshot
Founded in October 2022 by Dikla Berko-Ashur, Sakura Bio operates with 1–10 employees. The company has raised $1.7 million across one funding round from one investor.
Business overview
Sakura Bio is a Health Tech & Life Sciences company focused on developing an off-the-shelf, naive PBMC-derived allogeneic T-cell therapy to combat cancer, specifically acute myeloid leukemia. Its platform creates super-activated killer cells through a manipulation of naive PBMCs. The company's lead product, Super Activated Killer T-cell (SAK-T), is designed to offer superior anti-tumor cytotoxic activity without toxicity to healthy tissue, positioning it as a safe, off-the-shelf T-cell product in contrast to other T-cell-based therapies like CAR-T. Sakura Bio operates in the Pharma & Medical Biotechnology sector, targeting the Drugs Discovery & Development market.
Log in to access full profile ›Company Intelligence Q&A
- What is Sakura Bio's primary focus?
- Sakura Bio develops an off-the-shelf, naive PBMC-derived allogeneic T-cell therapy designed to fight cancer, particularly acute myeloid leukemia.
- What is the company's lead product?
- The company's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population engineered for superior anti-tumor cytotoxic activity.
- What is a key advantage of SAK-T cells?
- SAK-T cells offer a high safety profile with no graft-versus-host disease, allowing them to be developed as an off-the-shelf T-cell product.
- When was Sakura Bio founded?
- Sakura Bio was founded in October 2022.
- Who is a co-founder of Sakura Bio?
- Dikla Berko-Ashur is a co-founder and CEO of Sakura Bio.